Pacific biomarkers, inc.
ABSTRACT Pacific Biomarkers, Inc. is a recently incorporated, wholly owned subsidiary of Pacific Biometrics, Inc. (PBI), a specialty clinical trials laboratory. Pacific Biomarkers was created to provide biomarker testing services for clinical drug development, specifically in the areas of ligand-binding assays, multiplexing and immunogenicity testing, in a regulatory-compliant environment.
SourceAvailable from: Robert de larochelliere[Show abstract] [Hide abstract]
ABSTRACT: No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers. To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes. Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America (enrollment August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes. A total of 543 patients underwent coronary intravascular ultrasonography and were randomized to receive glimepiride, 1 to 4 mg, or pioglitazone, 15 to 45 mg, for 18 months with titration to maximum dosage, if tolerated. Atherosclerosis progression was measured by repeat intravascular ultrasonography examination in 360 patients at study completion. Change in percent atheroma volume (PAV) from baseline to study completion. Least squares mean PAV increased 0.73% (95% CI, 0.33% to 1.12%) with glimepiride and decreased 0.16% (95% CI, -0.57% to 0.25%) with pioglitazone(P = .002). An alternative analysis imputing values for noncompleters based on baseline characteristics showed an increase in PAV of 0.64% (95% CI, 0.23% to 1.05%) for glimepiride and a decrease of 0.06% (-0.47% to 0.35%) for pioglitazone (between-group P = .02). Mean (SD) baseline HbA(1c) levels were 7.4% (1.0%) in both groups and declined during treatment an average 0.55% (95% CI, -0.68% to -0.42%) with pioglitazone and 0.36% (95% CI, -0.48% to -0.24%) with glimepiride (between-group P = .03). In the pioglitazone group, compared with glimepiride, high-density lipoprotein levels increased 5.7 mg/dL (95% CI, 4.4 to 7.0 mg/dL; 16.0%) vs 0.9 mg/dL (95% CI, -0.3 to 2.1 mg/dL; 4.1%), and median triglyceride levels decreased 16.3 mg/dL (95% CI, -27.7 to -11.0 mg/dL; 15.3%) vs an increase of 3.3 mg/dL (95% CI, -10.7 to 11.7 mg/dL; 0.6%) (P < .001 for both comparisons). Median fasting insulin levels decreased with pioglitazone and increased with glimepiride (P < .001). Hypoglycemia was more common in the glimepiride group and edema, fractures, and decreased hemoglobin levels occurred more frequently in the pioglitazone group. In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride. clinicaltrials.gov Identifier: NCT00225277.JAMA The Journal of the American Medical Association 05/2008; 299(13):1561-73. DOI:10.1001/jama.299.13.1561 · 30.39 Impact Factor
Article: Protein arrays: growing pains.[Show abstract] [Hide abstract]
ABSTRACT: Protein microarrays are coming of age, and the development of specialized technologies is extending their high-throughput capabilities. Michael Eisenstein reports.Nature 01/2007; 444(7121):959-62. DOI:10.1038/444959a · 42.35 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: There is increasing evidence that human medical imaging can help answer key questions that arise during the drug development process. Imaging modalities such as magnetic resonance imaging, computed tomography and positron emission tomography can offer significant insights into the bioactivity, pharmacokinetics and dosing of drugs, in addition to supporting registration applications. In this review, examples from oncology, neurology, psychiatry, infectious diseases and inflammatory diseases are used to illustrate the role imaging can play. We conclude with some remarks concerning new developments that will be required to significantly advance the field of pharmaco-imaging.Drug Discovery Today 03/2005; 10(4):259-66. DOI:10.1016/S1359-6446(04)03334-3 · 5.96 Impact Factor